The Latest Breaking News from Bionano Genomics Inc

While Bionano Genomics (BNGO) is witnessing steady revenue growth, its bottom line remains in the red. Let’s dive deeper into its key financial metrics to analyze if BNGO is worth adding to your watchlists.

Genomic testing devices manufacturer Bionano Genomics (BNGO) is witnessing steady revenue growth. However, unfortunately, it did not translate into a bottom-line improvement. Moreover, as BNGO faces the possibility of delisting, is it worth buying now? Keep reading.

Biotech company Bionano Genomics (BNGO) has beaten analysts’ top-line estimate in the third quarter. However, its cash and cash equivalents balance has declined year-over-year. Therefore, is it a buy now under $3? Read on to find out….

Wall Street analysts expect Biotech stock Bionano Genomics (BNGO) to grow more than 160% in the near term. However, the stock’s fundamentals appear bleak, and the stock has lost more than 20% in 2022. Therefore, investors might avoid following Wall Street’s bullishness on this stock. Let’s find out….

The major market indexes have witnessed a massive sell-off recently. And this has significantly benefited short-sellers. Given the possibility of further market corrections, Lightning eMotors (ZEV), Bionano Genomics (BNGO), and QuantumScape (QS) could be ideal candidates for shorting this month, as they still look overvalued at their current price levels.